230 related articles for article (PubMed ID: 37343647)
1. Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation.
Zhou JB; Tang D; He L; Lin S; Lei JH; Sun H; Xu X; Deng CX
Pharmacol Res; 2023 Aug; 194():106830. PubMed ID: 37343647
[TBL] [Abstract][Full Text] [Related]
2. Natural inhibitors of PI3K/AKT signaling in breast cancer: emphasis on newly-discovered molecular mechanisms of action.
Safdari Y; Khalili M; Ebrahimzadeh MA; Yazdani Y; Farajnia S
Pharmacol Res; 2015 Mar; 93():1-10. PubMed ID: 25533812
[TBL] [Abstract][Full Text] [Related]
3. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
Roskoski R
Pharmacol Res; 2021 Jun; 168():105579. PubMed ID: 33774181
[TBL] [Abstract][Full Text] [Related]
4. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
5. Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies.
Wu W; Xue X; Chen Y; Zheng N; Wang J
Pharmacol Res; 2022 Oct; 184():106456. PubMed ID: 36116709
[TBL] [Abstract][Full Text] [Related]
6. UP12, a novel ursolic acid derivative with potential for targeting multiple signaling pathways in hepatocellular carcinoma.
Dong H; Yang X; Xie J; Xiang L; Li Y; Ou M; Chi T; Liu Z; Yu S; Gao Y; Chen J; Shao J; Jia L
Biochem Pharmacol; 2015 Jan; 93(2):151-62. PubMed ID: 25522955
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.
Ko JC; Chiu HC; Syu JJ; Jian YJ; Chen CY; Jian YT; Huang YJ; Wo TY; Lin YW
Biochem Pharmacol; 2014 Mar; 88(1):119-27. PubMed ID: 24447935
[TBL] [Abstract][Full Text] [Related]
8. Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy.
Wu M; Liu X; Jin W; Li Y; Li Y; Hu Q; Chu PK; Tang G; Ping Y
J Control Release; 2017 May; 253():110-121. PubMed ID: 28302581
[TBL] [Abstract][Full Text] [Related]
9. Targeting bromodomain and extraterminal proteins in breast cancer.
Sahni JM; Keri RA
Pharmacol Res; 2018 Mar; 129():156-176. PubMed ID: 29154989
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents.
Sampson A; Peterson BG; Tan KW; Iram SH
Biomed Pharmacother; 2019 Oct; 118():109289. PubMed ID: 31401398
[TBL] [Abstract][Full Text] [Related]
11. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
[TBL] [Abstract][Full Text] [Related]
12. Polyphyllin VI, a saponin from Trillium tschonoskii Maxim. induces apoptotic and autophagic cell death via the ROS triggered mTOR signaling pathway in non-small cell lung cancer.
Teng JF; Qin DL; Mei QB; Qiu WQ; Pan R; Xiong R; Zhao Y; Law BY; Wong VK; Tang Y; Yu CL; Zhang F; Wu JM; Wu AG
Pharmacol Res; 2019 Sep; 147():104396. PubMed ID: 31404628
[TBL] [Abstract][Full Text] [Related]
13. Network pharmacology analysis of the anti-cancer pharmacological mechanisms of Ganoderma lucidum extract with experimental support using Hepa1-6-bearing C57 BL/6 mice.
Zhao RL; He YM
J Ethnopharmacol; 2018 Jan; 210():287-295. PubMed ID: 28882624
[TBL] [Abstract][Full Text] [Related]
14. Advances in molecular mechanisms of drugs affecting abnormal glycosylation and metastasis of breast cancer.
Liu H; Ma L; Lin J; Cao B; Qu D; Luo C; Huang W; Han L; Xu H; Wu Z; Xu R; Zhang D
Pharmacol Res; 2020 May; 155():104738. PubMed ID: 32151681
[TBL] [Abstract][Full Text] [Related]
15. Staurosporine and venetoclax induce the caspase-dependent proteolysis of MEF2D-fusion proteins and apoptosis in MEF2D-fusion (+) ALL cells.
Tange N; Hayakawa F; Yasuda T; Odaira K; Yamamoto H; Hirano D; Sakai T; Terakura S; Tsuzuki S; Kiyoi H
Biomed Pharmacother; 2020 Aug; 128():110330. PubMed ID: 32504922
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR.
Sun WX; Han HW; Yang MK; Wen ZL; Wang YS; Fu JY; Lu YT; Wang MY; Bao JX; Lu GH; Qi JL; Wang XM; Lin HY; Yang YH
Bioorg Med Chem; 2019 Dec; 27(23):115153. PubMed ID: 31648877
[TBL] [Abstract][Full Text] [Related]
17. New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
He Y; Luo Y; Huang L; Zhang D; Wang X; Ji J; Liang S
Pharmacol Res; 2021 Aug; 170():105732. PubMed ID: 34139345
[TBL] [Abstract][Full Text] [Related]
18. Targeting Akt/PKB in pediatric tumors: A review from preclinical to clinical trials.
Toson B; Fortes IS; Roesler R; Andrade SF
Pharmacol Res; 2022 Sep; 183():106403. PubMed ID: 35987481
[TBL] [Abstract][Full Text] [Related]
19. Hyperbranched-hyperbranched polymeric nanoassembly to mediate controllable co-delivery of siRNA and drug for synergistic tumor therapy.
Jia HZ; Zhang W; Zhu JY; Yang B; Chen S; Chen G; Zhao YF; Feng J; Zhang XZ
J Control Release; 2015 Oct; 216():9-17. PubMed ID: 26272764
[TBL] [Abstract][Full Text] [Related]
20. The effects of estrogen on targeted cancer therapy drugs.
Zhao Y; Wang X; Liu Y; Wang HY; Xiang J
Pharmacol Res; 2022 Mar; 177():106131. PubMed ID: 35167895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
